Financial Data and Key Metrics Changes - Total revenues for Q4 2025 reached RMB 1.18 billion, reflecting a year-over-year increase of 32.2% [4][20] - Net income for Q4 2025 was RMB 337.4 million, up 15.4% year-over-year, with a net margin of 28.7% [4][23] - For the full year 2025, total revenues reached RMB 4.37 billion, representing a year-over-year increase of 33.1% [4][24] - Net income for the full year was RMB 1.31 billion, up 51% year-over-year, with a net margin of 29.9% [5][24] - Cash reserves at the end of 2025 were RMB 4.04 billion, up 72.9% year-over-year [6][25] Business Line Data and Key Metrics Changes - Revenues from insurance distribution services for Q4 2025 reached RMB 4,401.1 million, a 35.1% year-over-year increase [20][21] - Revenues from system services totaled RMB 774.1 million, up 31.1% year-over-year [21] - For the full year, revenues from insurance distribution services reached RMB 1.45 billion, up 33.8% year-over-year, while revenues from system services totaled RMB 2.92 billion, growing by 33.2% [23][24] Market Data and Key Metrics Changes - The number of new policies increased by 34.5% year-over-year to approximately 7.9 million in Q4 2025 [7] - For the full year, new policies reached approximately 30.7 million, representing a year-over-year increase of 36.7% [7] Company Strategy and Development Direction - The company is focused on leveraging AI technology to enhance operational efficiency and improve service delivery [10][18] - The strategic direction includes expanding the insurance product matrix and enhancing accessibility and affordability for users [14][16] - The company aims to integrate large-scale AI models with insurance scenarios to create value across the insurance value chain [18][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining revenue and net profit growth momentum in 2026 despite intensifying industry competition [29] - The company is well-positioned to convert supportive health insurance policies into long-term business growth [45] - The ongoing advancements in AI are expected to enhance the company's competitive edge and operational capabilities [51] Other Important Information - The company has implemented intelligent operations across key areas such as product customization and claims processing, improving service efficiency [10][12] - The focus on technological advancements aims to create sustainable commercial value alongside meaningful social value [19] Q&A Session Summary Question: Top line and bottom line growth guidance for 2026 - Management did not provide specific earnings guidance for 2026 but expects to maintain growth momentum [29] Question: Dividend plans for the coming year - The company is evaluating strategies to maximize shareholder returns, including potential dividend policies, but did not provide a specific timeline [33] Question: 2026 outlook on sales and marketing costs - Management expects customer demand to remain healthy and aims to maintain sales and marketing expenses as a percentage of revenue broadly stable [36] Question: Contribution breakdown between new and existing users - The majority of current users are new users, with customer renewal rates remaining stable [39] Question: Future policy drivers for commercial health insurance - Recent policies emphasize the importance of inclusive development and expanding the reach of commercial insurance [45] Question: Development of AI agents and their impact - AI agents are seen as promising, but their effectiveness depends on specific usage scenarios [48] Question: Impact of AI application iterations on business - The company is focused on large-scale implementation of AI, enhancing its competitive edge through deep vertical expertise and data capabilities [51]

Financial Data and Key Metrics Changes - In Q4 2025, Macy's, Inc. reported net sales of $7.6 billion, exceeding guidance of $7.35-$7.5 billion, but down from $7.8 billion last year [22] - Comparable sales rose 1.8%, significantly above guidance of down 2.5% to flat, with go-forward business comparable sales growth of 2% [23] - Adjusted diluted EPS was $1.67, exceeding the guidance range of $1.35-$1.55, despite a tariff impact of approximately $0.13 [26] Business Line Data and Key Metrics Changes - Macy's nameplate achieved 0.6% go-forward comparable sales growth, a 190 basis points improvement year-over-year [10] - Bloomingdale's saw a remarkable 9.9% comparable sales growth, marking its best holiday result on record [23] - Bluemercury achieved 1.6% annual comparable sales growth, driven by strong performance in dermatological skincare and fragrances [15] Market Data and Key Metrics Changes - Macy's digital channel represents approximately one-third of annual sales, benefiting from a modernized online presence [11] - The company reported a strong performance in holiday destination categories, including fragrances, jewelry, and handbags, which outperformed expectations [9] - The Macy's Thanksgiving Day Parade drew over 34 million viewers, generating significant social media impressions, which were leveraged into retail offerings [9] Company Strategy and Development Direction - The "A Bold New Chapter" strategy focuses on sustainable profitable growth, with a strong emphasis on customer engagement and operational efficiency [7][39] - The company plans to expand the Reimagine program to 200 locations, which will account for approximately 60% of the go-forward Macy's store base [17] - Macy's is committed to enhancing its omnichannel experience and investing in local market strengths to drive customer engagement [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate macroeconomic uncertainties while building on recent momentum [20] - The company is taking a prudent approach to guidance, reflecting both optimism about its strategy and caution regarding external factors [20] - Management highlighted the importance of maintaining a balanced approach to pricing and promotions to appeal to a diverse consumer base [56] Other Important Information - Macy's achieved a free cash flow yield of over 15%, with operating cash flow of $1.4 billion for the year [26] - The company returned $448 million to shareholders, including $197 million in cash dividends, marking a 27% increase in annual payout since 2021 [28] - The company is focused on leveraging AI across various operational areas to enhance customer experience and drive efficiencies [31] Q&A Session Summary Question: How does Macy's plan to remain resilient amidst consumer volatility? - Management expressed confidence in the company's growth across all nameplates and highlighted a healthy balance sheet and inventory levels as key strengths [42][43] Question: What are the expectations for AUR versus units in the upcoming year? - Management noted that AUR has been growing, reflecting improved assortments and customer engagement, while overall basket size is increasing despite a slight decline in units [44] Question: What actions are being taken to appeal to price-sensitive consumers? - Management emphasized a balanced promotional strategy that caters to both value-seeking and brand-conscious consumers, leveraging a diverse product portfolio [56] Question: What drove upside performance in Q4 and thoughts on private brands? - Management highlighted strong growth in women's contemporary apparel and fine jewelry, while private brands remain a focus for improvement and expansion [73] Question: What are the plans for store closures and openings? - Management indicated that approximately 65 store closures will be extended through 2028, with a focus on optimizing the store fleet to support the omnichannel business [67]

Financial Data and Key Metrics Changes - In 2025, XOMA Royalty reported total GAAP income and revenue of $52.1 million, a significant increase from $28.5 million in 2024 [21] - Total cash receipts grew by 9% to $50.5 million, with royalty receipts reaching approximately $34 million, marking a 68% increase compared to 2024 [21] - Full-year GAAP net income was $31.7 million, compared to a GAAP net loss of $13.8 million in 2024 [23] Business Line Data and Key Metrics Changes - The company added 22 assets to its portfolio in 2025, including five in phase II or phase III trials, with a total cash outlay of only $25 million upfront [14] - Royalty receipts came from four programs in 2025, two more than in 2024, and six programs achieved clinical, regulatory, and business development events, leading to approximately $17 million in cash milestone payments [21] Market Data and Key Metrics Changes - The portfolio has expanded significantly, doubling the number of assets in active development from roughly 60 in 2023 to over 120 in 2025 [12] - The company has established a diverse and growing source of recurring receipts, with seven commercially available programs [5] Company Strategy and Development Direction - XOMA Royalty aims to build a diversified portfolio of biotechnology royalty and milestone assets while maintaining disciplined capital allocation [11] - The company is focused on innovative transactions and underappreciated opportunities, positioning itself as a unique source of capital for biotech innovation [20] - The strategy includes a balance between returning capital to shareholders and investing in new portfolio assets to increase breadth [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for royalty receipts, particularly from VABYSMO, OJEMDA, and MIPLYFFA, which are expected to ramp up significantly [32] - The company is approaching an inflection point where royalty receipts alone could cover operating expenses by 2027 [28] - Management remains optimistic about the potential for future milestone payments and royalty growth from a robust late-stage pipeline [9] Other Important Information - The company maintained a lean operating structure, achieving positive cash flow from operations and returning $16 million of capital through share buybacks [5] - XOMA Royalty ended the year with approximately $83 million in unrestricted cash and cash equivalents, providing ample firepower for future investments [27] Q&A Session Summary Question: Growth prospects for royalty receipts on approved products - Management indicated strong growth prospects, particularly from VABYSMO, which had double-digit growth last year, and positive expectations for OJEMDA and MIPLYFFA [32] Question: Confidence in Tremfya economic opportunity - Management expressed confidence in the breach claim related to Tremfya, citing historical relationships and potential royalty rates [34] Question: Prioritization of capital deployment between share buybacks and new deals - Management emphasized a philosophy of reducing equity base to increase cash flow per share while balancing external opportunities [46] Question: Size of the opportunity for Rezolute's ersodetug program - Management estimated the combined opportunity for the two indications to be approaching $1 billion, with a favorable split between congenital and tumor hyperinsulinism [48]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 reached CNY 1.18 billion, reflecting a year-over-year increase of 32.2% [4] - Net income for Q4 2025 was CNY 337.4 million, up 15.4% year-over-year, with a net margin of 28.7% [4] - For the full year 2025, total revenues reached CNY 4.37 billion, representing a year-over-year increase of 33.1% [5] - Net income for the full year was CNY 1.31 billion, up 51% year-over-year, with a net margin of 29.9% [5][24] - Cash reserves at the end of 2025 were CNY 4.04 billion, up 72.9% year-over-year [6][25] Business Line Data and Key Metrics Changes - New policies in Q4 2025 increased by 34.5% year-over-year to approximately 7.9 million [7] - For the full year, new policies reached approximately 30.7 million, representing a year-over-year increase of 36.7% [7] - Revenues from insurance distribution services for Q4 2025 reached CNY 4,401.1 million, a 35.1% year-over-year increase [20] - Revenues from system services totaled CNY 774.1 million, up 31.1% year-over-year [21] Market Data and Key Metrics Changes - The commercial health insurance industry is entering a new phase of high-quality development, supported by government policies [8] - The government work report emphasizes the importance of improving the multi-tiered healthcare security system and accelerating the development of commercial health insurance [8] Company Strategy and Development Direction - The company aims to leverage technology to promote inclusive insurance and deepen its focus on AI integration across operations [18] - The strategy includes expanding the insurance product matrix and enhancing accessibility and affordability for users [14][16] - The company is committed to aligning with national policy priorities and contributing to the development of a multi-tiered healthcare security system [19] Management's Comments on Operating Environment and Future Outlook - Management expects to maintain revenue and net profit growth momentum in 2026 despite intensifying industry competition [29] - The company is focused on scaling operations, driving high-quality growth, and enhancing operational efficiency [25] - The ongoing wave of AI application iterations is seen as a significant opportunity for the company to enhance its business model [52] Other Important Information - The company has implemented intelligent operations across key areas such as product customization and claims processing, enhancing service efficiency [10][12] - The AI team accounted for over 10% of the total workforce, indicating a strong focus on technological capabilities [7] Q&A Session Summary Question: Guidance on top line and bottom line growth for 2026 - Management did not provide specific earnings guidance for 2026 but expects to maintain growth momentum [29] Question: Dividend plans for the coming year - The company is evaluating strategies to maximize shareholder returns, including potential dividend policies, but did not provide a specific timeline [33] Question: Outlook on sales and marketing costs for 2026 - Management expects customer demand to remain healthy and aims to maintain sales and marketing expenses as a percentage of revenue broadly stable [36] Question: Contribution breakdown between new and existing users - The majority of current users are new users, with customer renewal rates remaining stable [39] Question: Future policy drivers for commercial health insurance - Recent policies are expected to serve as catalysts for expanding the reach of commercial insurance and enhancing product value [44][45] Question: Development of AI agents and their impact - AI agents are seen as promising, but their effectiveness depends on specific usage scenarios [48] Question: Impact of AI application iterations on the business - The company believes AI will evolve into a full-cycle intelligent service ecosystem, enhancing its competitive edge [53]

Financial Data and Key Metrics Changes - In Q4 2025, the company generated total revenue of RMB 2.08 billion, up 14% year-on-year [5] - For the full year 2025, total revenue reached RMB 8.27 billion, an increase of 12.4% year-on-year [7] - Adjusted operating profit for Q4 was RMB 900 million, up 37% year-on-year, while for the full year it reached RMB 3.38 billion, up 45.7% year-on-year [6][8] - The adjusted operating profit margin for the full year improved to 40.8% [8] Business Line Data and Key Metrics Changes - The number of paid enterprise customers reached 6.83 million, up 11.6% year-on-year [12] - Revenue from small-sized accounts grew 21% year-on-year, outpacing mid-sized and key accounts [29] - The average monthly active users (MAU) of the BOSS Zhipin app reached over 60.7 million, representing a year-on-year increase of 14.5% [9] Market Data and Key Metrics Changes - Revenue contribution from third-tier and lower-tier cities approached 25% in Q4, doubling compared to four years ago [11] - The growth rate of blue-collar users led the overall user base, with their contribution to revenue further increasing [10] - AI-related job postings grew by 172% year-on-year, indicating a surge in demand for AI-related talents [48] Company Strategy and Development Direction - The company aims to strengthen its commitment to shareholder returns, planning to allocate no less than 50% of the prior year's adjusted net income for dividends and share repurchases over the next three years [26] - The company is focusing on AI advancements to enhance recruitment efficiency and create closed-loop services [19][20] - The strategy includes penetrating the blue-collar sector and lower-tier cities, which has shown significant growth potential [10] Management Comments on Operating Environment and Future Outlook - Management noted a steady recovery in the recruitment market, with strong demand expected to continue through the spring recruitment season [14][37] - The company anticipates total revenues for Q1 2026 to be between RMB 2.050 billion and RMB 2.085 billion, reflecting a year-on-year increase of 6.6% to 8.4% [37] - Management expressed confidence in the long-term growth potential despite challenges posed by AI technology [56] Other Important Information - The company reported a net cash position of RMB 19.9 billion as of December 31, 2025, which will be leveraged for future growth initiatives [35] - The company declared a dividend of $80 million for 2025 and has already repurchased $50 million worth of shares in 2026 [36] Q&A Session Summary Question: Concerns about AI's impact on white-collar jobs and competitive advantage - Management acknowledged the debate around AI potentially reducing demand for white-collar jobs but emphasized that AI can enhance labor efficiency and create new job opportunities [40][43] Question: Plans for AI product testing and monetization expectations - Management expects significant revenue growth from closed-loop placement services, potentially doubling or tripling this year [61] Question: User growth targets for 2026 and margin trends - The company aims to add at least 40 million newly verified users in 2026 and expects slight margin improvement despite increased investments in AI [72]

Financial Data and Key Metrics Changes - In 2025, the group revenue grew 5.9% year-over-year to RMB 25.3 billion, with Legacy-Huazhu's revenue rising by 7.9% to RMB 20.5 billion [28][29] - Group adjusted EBITDA increased 24.2% year-over-year to RMB 8.5 billion, with a margin improvement of 4.9 percentage points to 33.5% [28][29] - Adjusted net income rose by 32.9% year-over-year to RMB 4.9 billion [29] Business Line Data and Key Metrics Changes - The managed and franchised revenue increased by 23.1% year-over-year to RMB 11.7 billion, with gross operating profit rising by 20.8% to RMB 7.6 billion [30] - Room nights sold to members rose 21.5% year-over-year, exceeding 245 million in 2025 [11] - The asset-light monetized and franchised business delivered solid growth, contributing 69% to the overall profit in 2025, a 5 percentage point increase year-over-year [30] Market Data and Key Metrics Changes - Demand for travel in China is shifting from discretionary to necessity, with a steady increase in trips and consumer spending [5][6] - The hotel industry faces an oversupply of low-quality products, while high-quality, value-for-money options remain insufficient [6][7] - The company is focusing on lower-tier cities and rural areas to fill the gap in quality accommodation [8] Company Strategy and Development Direction - The company aims to deepen its roots in the China market, focusing on high-quality growth and service excellence [9][19] - A multi-brand strategy is being employed in the upper mid-scale segment, with four key brands targeting different market niches [63][66] - The introduction of the HanTing Inn brand aims to balance cost-effectiveness and quality, catering to family and group travel needs [15][50] Management's Comments on Operating Environment and Future Outlook - The management is cautiously optimistic about the overall RevPAR performance for 2026, expecting a flat to slight year-over-year increase [44] - The company plans to continue enhancing customer experience and operational efficiency while pursuing a strategic goal of 2,000 cities and 20,000 hotels [19][32] - The Legacy-DH business has achieved a successful turnaround, with a record adjusted EBITDA of around RMB 500 million [22] Other Important Information - The company declared a $400 million cash dividend for the second half of 2025, contributing to a total shareholder return of around $760 million for the year [31][32] - The company has completed over 75% of its $2 billion three-year shareholder return plan [32] Q&A Session Summary Question: Direction of Arthur's new role and expected changes - Management expressed confidence in Arthur Yu's expertise to lead the company towards becoming a global, world-class entity [39] Question: 2026 revenue guidance and demand-supply outlook - Management noted a recovering trend in the hotel industry, with growing demand for leisure and business travel, and cautiously optimistic RevPAR expectations for 2026 [43][44] Question: Hotel opening pace and new brands - The company plans to open 2,200-2,300 new hotels in 2026, focusing on high-quality standards [48] Question: Asset-light transformation strategy for DH - Management highlighted ongoing efforts in cost control and portfolio restructuring, with confidence in expanding the hotel network internationally [56] Question: Future shareholder return plans - The company is committed to returning value to shareholders through dividends and share repurchases, supported by strong cash flow [59] Question: Plans for upper mid-scale hotel segment - The upper mid-scale segment remains a strategic focus, with plans for continued development and brand enhancement [63][66]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was RMB 194.4 billion, up 13% year-on-year [36] - Gross profit increased to RMB 108.3 billion, reflecting a 19% year-on-year growth [36] - Non-IFRS operating profit was RMB 69.5 billion, up 17% year-on-year [37] - Non-IFRS net profit attributable to equity holders was RMB 64.7 billion, also up 17% year-on-year [37] - Overall gross margin improved to 56%, up 3 percentage points year-on-year [38] Business Line Data and Key Metrics Changes - Value-added services (VAS) revenue was RMB 90 billion, up 14% year-on-year, with social network revenue growing 3% to RMB 31 billion [27] - Domestic games revenue increased by 15% year-on-year, driven by titles like Delta Force and Valorant [28] - International games revenue surged by 32% year-on-year, primarily from Supercell's titles and PUBG Mobile [28] - Marketing services revenue rose 17% year-on-year to RMB 41 billion, benefiting from improved ad targeting and AI enhancements [31] - Fintech and business services revenue was RMB 61 billion, up 8% year-on-year, with fintech services growing modestly [33] Market Data and Key Metrics Changes - Video Accounts saw total time spent increase by over 20% due to enhanced content recommendation algorithms [16] - The international games business surpassed $10 billion in annual revenue for the first time [5] - Tencent Cloud achieved RMB 5 billion adjusted operating profit, reflecting a significant turnaround from previous losses [25] Company Strategy and Development Direction - The company is focusing on AI as a transformational force, integrating it into existing businesses to enhance user engagement and operational efficiency [8][13] - Investments in new AI products are expected to double in 2026, funded by increasing earnings from core businesses [23] - The strategy includes leveraging AI to reinforce core businesses while exploring new product opportunities [12][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of core businesses amid AI advancements, highlighting strong user engagement and revenue trends [10][13] - The company anticipates that revenue growth may outpace profit growth in 2026 due to increased investments in AI [47] - Management emphasized the importance of building a strong AI talent team and securing GPU resources to support AI initiatives [50][51] Other Important Information - The company plans to propose an annual dividend of HKD 5.3 per share, reflecting an 18% year-on-year increase [43] - Free cash flow for Q4 2025 was RMB 34 billion, increasing over six times year-on-year [40] - The company repurchased 153 million shares in 2025, totaling HKD 80 billion [41] Q&A Session Summary Question: AI investment impact on margins - Management acknowledged that revenue growth might exceed profit growth in 2026 due to AI investments, which are seen as long-term opportunities [47][48] Question: Resource allocation for AI development - Management confirmed that they are actively hiring top AI talent and securing GPU resources to prioritize AI product development [50][51] Question: ROI assessment for AI investments - Management indicated that initial investments in AI products are expected to yield attractive returns over time, similar to the trajectory of Tencent Cloud [57] Question: Differentiation in AI stack - Management highlighted the importance of investing across all layers of the AI stack, leveraging Tencent's strengths in product capability and ecosystem [60][70] Question: Value proposition in the agentic era - Management emphasized Tencent's unique capabilities across devices and applications, positioning the company well for the deployment of agentic AI services [75][78]

Financial Data and Key Metrics Changes - In 2025, the group revenue grew 5.9% year-over-year to CNY 25.3 billion, with Legacy-Huazhu's revenue rising by 7.9% to CNY 20.5 billion [26][27] - Group adjusted EBITDA increased 24.2% year-over-year to CNY 8.5 billion, with a margin improvement of 4.9 percentage points to 33.5% [26][27] - Adjusted net income rose by 32.9% year-over-year to RMB 4.9 billion [27][28] Business Line Data and Key Metrics Changes - The managed and franchised revenue increased by 23.1% year-over-year to RMB 11.7 billion, with gross operating profit rising by 20.8% to RMB 7.6 billion [27][28] - Room nights sold to members rose 21.5% year-over-year, exceeding 245 million in 2025 [11] - The number of rooms in operation increased by 16.2% year-over-year, contributing to a group hotel GMV growth of 16.4% to CNY 108.1 billion [11] Market Data and Key Metrics Changes - Demand for travel in China is shifting from discretionary to necessity, with increasing trips and consumer spending [5][6] - The hotel industry faces oversupply of low-quality products, while high-quality supply remains insufficient [6][7] Company Strategy and Development Direction - The company focuses on supply-side reform, targeting high-quality growth in the economy and mid-scale segments [7][8] - Plans to expand into lower-tier cities and rural areas to fill gaps in quality accommodation [8][9] - Aiming for a strategic goal of 2,000 cities and 20,000 hotels by 2030 [19] Management's Comments on Operating Environment and Future Outlook - Management is cautiously optimistic about RevPAR performance in 2026, expecting a flat to slight year-over-year increase [42][43] - The company will continue to enhance customer experience and operational efficiency while leveraging technology [19][24] Other Important Information - The company declared a $400 million cash dividend for the second half of 2025, with total shareholder returns amounting to around $760 million for the year [29][30] - The company completed over 75% of its $2 billion three-year shareholder return plan [29] Q&A Session Summary Question: Direction of Arthur's new role and expected changes - Management expressed confidence in Arthur Yu's expertise to lead financial strategy and support growth trajectory [34][38] Question: 2026 revenue guidance and demand-supply outlook - Management noted a recovering hotel industry trend, with growing leisure travel and business activity in Tier 1 and Tier 2 cities [42][43] Question: Hotel opening pace and new brands - The company plans to open 2,200-2,300 new hotels in 2026, focusing on high-quality standards [46][47] Question: Asset lighter transformation strategy for DH - Management discussed ongoing cost control and portfolio restructuring, with confidence in managing international hotels [52][53] Question: Future shareholder return plans - The company is committed to returning to shareholders through dividends or share repurchases, supported by strong cash flow [56] Question: Plans for upper mid-scale hotel segment - The upper mid-scale segment remains a strategic focus, with plans for continued development using a multi-brand strategy [60][62]

Financial Data and Key Metrics Changes - In Q4 2025, the company generated total revenue of RMB 2.08 billion, up 14% year-on-year [5] - For the full year 2025, total revenue reached RMB 8.27 billion, an increase of 12.4% year-on-year [7] - Adjusted operating profit for Q4 was RMB 900 million, up 37% year-on-year, while for the full year, it reached RMB 3.38 billion, up 45.7% year-on-year [6][7] - The adjusted operating profit margin for the full year improved to 40.8% [7] Business Line Data and Key Metrics Changes - The number of paid enterprise customers reached 6.83 million, up 11.6% year-on-year [12] - Revenue from small-sized accounts grew 21% year-on-year, outpacing mid-sized and key accounts [30] - The average revenue per paying user (ARPPU) remained broadly stable despite increased revenue contribution from SMEs [12] Market Data and Key Metrics Changes - The average monthly active users (MAU) of the BOSS Zhipin app reached over 60.7 million, representing a year-on-year increase of 14.5% [9] - The platform facilitated over 2.27 billion instances of mutual consent exchanges, a year-on-year growth of 22.4% [9] - Revenue contribution from third-tier and lower-tier cities approached 25%, doubling compared to four years ago [11] Company Strategy and Development Direction - The company is focusing on enhancing its AI capabilities to deliver closed-loop services, aiming to improve matching efficiency for job seekers and enterprises [19][20] - There is a commitment to shareholder returns, with plans to allocate no less than 50% of the prior year's adjusted net income for dividends and share repurchases over the next three years [27] - The company is actively penetrating the blue-collar sector and lower-tier cities, with significant growth in user acquisition from these markets [10][11] Management's Comments on Operating Environment and Future Outlook - Management noted robust momentum in both supply and demand during the spring recruitment season, with a healthy job seeker to enterprise user ratio [13][17] - The company expects total revenues for Q1 2026 to be between RMB 2.050 billion and RMB 2.085 billion, reflecting a year-on-year increase of 6.6% to 8.4% [38] - Management expressed confidence in the long-term growth potential despite challenges posed by AI, highlighting a surge in demand for AI-related jobs [48][50] Other Important Information - The company declared a dividend of $80 million for 2025 and has already repurchased $50 million worth of shares in 2026 [36] - The cash position stood at RMB 19.9 billion as of December 31, 2025, which will be leveraged for future growth initiatives [36] Q&A Session Summary Question: Concerns about AI's impact on white-collar jobs - Management acknowledged the debate around AI potentially reducing demand for white-collar jobs but emphasized that AI can enhance labor efficiency and create new job opportunities [41][44] Question: Plans for AI product testing and monetization - Management expects significant revenue growth from closed-loop placement services, anticipating that revenue could double or triple this year [61] Question: User growth target for 2026 and margin trends - The company aims to add at least 40 million newly verified users in 2026 and expects overall adjusted operating profit margins to slightly increase despite investments in AI [72]

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - As of December 31, 2025, the company held $30.3 million in cash equivalents and short-term bank deposits, with a projected cash balance of approximately $50 million by early April 2026 [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [11] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [11] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [5] - The approval of the every four weeks regimen in Europe is expected to significantly enhance Elfabrio's market uptake [5] Company Strategy and Development Direction - The company aims to advance its clinical pipeline, including PRX-115 and PRX-119, while maintaining a strong financial position to support these initiatives [12] - The company is focused on expanding its renal pipeline and expects to provide updates on specific indications and mechanisms of action in the coming months [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial flexibility and growth trajectory, projecting revenue growth in 2026 of greater than 50% [12] - The approval of the every four weeks regimen in Europe is seen as a significant competitive edge, with expectations for accelerated approval in the U.S. [17] Other Important Information - The company anticipates top-line results from the PRX-115 RELEASE study in the second half of 2027 [6] - The company is expanding its renal pipeline through collaborations and new candidates [7] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. and sales trajectory in Europe - Management highlighted ongoing promotional activities by Chiesi, including patient ambassador programs, and noted that the approval of the four-week regimen in Europe is expected to enhance market positioning [16] Question: Positioning of PRX-115 in the gout market - Management discussed the potential competitive advantages of PRX-115, including dosing frequency and safety, and projected a significant market opportunity for uncontrolled gout [18][20] Question: Target indications for PRX-119 and potential commercial opportunities - Management indicated that they are targeting high unmet need renal indications and will provide updates on specific mechanisms of action in the future [22][23] Question: Timeline for rollout of Elfabrio's four-week dosing in Europe - Management stated that availability will vary by country, with expectations for rollout starting in the second half of 2026 [27][30] Question: Physician education efforts accompanying the rollout - Management confirmed that Chiesi is actively engaging with treating physicians and stakeholders to promote the new regimen [31]